Proteolysis-targeting chimera against NR4A1 for cancer immunotherapy

被引：0
|
作者：
Wang, Lei
Xiao, Yufeng
Master, Rohan P.
Jin, Zeng
Patel, Urvi M.
Luo, Yuewan
Zhou, Daohong
Zheng, Guangrong
Zhang, Weizhou
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-2326
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2326
引用
收藏
页数：2
相关论文
共 50 条
  • [21] PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy
    Wang, Lei
    Xiao, Yufeng
    Luo, Yuewan
    Master, Rohan P.
    Mo, Jiao
    Kim, Myung-Chul
    Liu, Yi
    Maharjan, Chandra K.
    Patel, Urvi M.
    De, Umasankar
    Carelock, Madison E.
    Tithi, Tanzia Islam
    Li, Xiangming
    Shaffer, Donald R.
    Guertin, Kevin R.
    Zhuang, Haoyang
    Moser, Emily
    Smalley, Keiran S. M.
    Lv, Dongwen
    Zhou, Daohong
    Zheng, Guangrong
    Zhang, Weizhou
    JOURNAL OF EXPERIMENTAL MEDICINE, 2024, 221 (03):
  • [22] Development of oridonin-based proteolysis-targeting chimera (PROTAC) degraders as effective breast cancer therapeutics
    Ma, Ruixia
    Wang, Pingyuan
    Xu, Junhai
    Xu, Jimin
    Fricke, Doerte R.
    Xue, Yu
    Kim, Hyejin
    Chen, Haiying
    Liu, Xi
    Zhou, Jia
    Shen, Qiang
    CANCER RESEARCH, 2022, 82 (12)
  • [23] Discovery of Novel Proteolysis-Targeting Chimera Molecules as Degraders of Programmed Cell Death-Ligand 1 for Breast Cancer Therapy
    Zhang, Hongjia
    Zhang, Yan
    Feng, Zhanzhan
    Shuai, Ming
    Ma, Xinyu
    Wang, Shirui
    Yu, Su
    Deng, Rui
    Luo, Dan
    Shi, Jianyou
    Pu, Chunlan
    Li, Rui
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (13) : 10589 - 10600
  • [24] Proteolysis-targeting chimeras (PROTACs) in cancer therapy
    Li, Xinyi
    Pu, Wenchen
    Zheng, Qingquan
    Ai, Min
    Chen, Song
    Peng, Yong
    MOLECULAR CANCER, 2022, 21 (01)
  • [25] Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells
    Kolb, Ryan
    De, Umasankar
    Khan, Sajid
    Luo, Yuewan
    Kim, Myung-Chul
    Yu, Haijun
    Wu, Chaoyan
    Mo, Jiao
    Zhang, Xin
    Zhang, Peiyi
    Zhang, Xuan
    Borcherding, Nicholas
    Koppel, Daniel
    Fu, Yang-Xin
    Zheng, Song Guo
    Avram, Dorina
    Zheng, Guangrong
    Zhou, Daohong
    Zhang, Weizhou
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [26] Proteolysis-Targeting Chimera (PROTAC) Delivery into the Brain across the Blood-Brain Barrier
    Tashima, Toshihiko
    ANTIBODIES, 2023, 12 (03)
  • [27] Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance
    Salami, Jemilat
    Alabi, Shanique
    Willard, Ryan R.
    Vitale, Nick J.
    Wang, Jing
    Dong, Hanqing
    Jin, Meizhong
    McDonnell, Donald P.
    Crew, Andrew P.
    Neklesa, Taavi K.
    Crews, Craig M.
    COMMUNICATIONS BIOLOGY, 2018, 1
  • [28] Promising Proteolysis-Targeting Chimera for Mutant p53-R175H
    Zhuang, Xinzhe
    Guo, Yidan
    Sun, Xiaozi
    Chen, Jie
    Xie, Songbo
    Yang, Fengtang
    Li, Jingrui
    ACS OMEGA, 2024, 9 (45): : 45138 - 45146
  • [29] Selective CDK9 degradation using a proteolysis-targeting chimera (PROTAC) strategy
    Mallareddy, Jayapal Reddy
    Singh, Sarbjit
    Boghean, Lidia
    Natarajan, Amarnath
    FUTURE MEDICINAL CHEMISTRY, 2022, 14 (03) : 131 - 134
  • [30] Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase
    Degorce, Sebastien L.
    Tavana, Omid
    Banks, Erica
    Crafter, Claire
    Gingipalli, Lakshmaiah
    Kouvchinov, David
    Mao, Yumeng
    Pachl, Fiona
    Solanki, Anisha
    Valge-Archer, Viia
    Yang, Bin
    Edmondson, Scott D.
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (18) : 10460 - 10473
12345